CVAC Live signals | Maximize Profits with Getagraph.com

BUY 135005 min ago

@ $3.41

Issued: 14 Feb 2024 @ 15:58

Return: 2.50%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: -2.14 %

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA)...

Stats
Today's Volume	2.39M
Average Volume	751 712
Market Cap	781.35M
EPS	$-0.240 ( 2023-11-14 )
Next earnings date	( $-0.220 ) 2024-06-04
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.73
ATR14	$0.0150 (0.43%)

Volume Correlation

Long: -0.02 (neutral)

Short: 0.66 (moderate)

Signal:(56.242) Neutral

CureVac AG Correlation

10 Most Positive Correlations
NDLS	0.949
NVTS	0.946
CWCO	0.943
ADPT	0.94
ASLE	0.939
EBTC	0.937
CFFI	0.937
CLNE	0.936
BELFA	0.934
BGFV	0.93

10 Most Negative Correlations
RNLC	-0.93
SWAV	-0.917
MCAA	-0.916
VMGA	-0.912
HCNE	-0.907
GHRS	-0.907
ADAL	-0.906
JVA	-0.905
ESTA	-0.904
IMPPP	-0.904

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CureVac AG Correlation - Currency/Commodity

0.26
( neutral )

0.11
( neutral )

0.00
( neutral )

-0.41
( neutral )

0.00
( neutral )

-0.46
( neutral )

CureVac AG Financials

Annual	2023
Revenue:	$52.66M
Gross Profit:	$-91.08M (-172.97 %)
EPS:	$-1.150

FY	2023
Revenue:	$52.66M
Gross Profit:	$-91.08M (-172.97 %)
EPS:	$-1.150

FY	2022
Revenue:	$67.42M
Gross Profit:	$-116.57M (-172.91 %)
EPS:	$-1.320

FY	2021
Revenue:	$102.99M
Gross Profit:	$-135.21M (-131.28 %)
EPS:	$-2.28

Financial Reports:

No articles found.

CureVac AG Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

CureVac AG

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.